Oncolytics Biotech Inc (TO:ONC) — Market Cap & Net Worth
Market Cap & Net Worth: Oncolytics Biotech Inc (ONC)
Oncolytics Biotech Inc (TO:ONC) has a market capitalization of $142.51 Million (CA$197.01 Million) as of May 4, 2026. Listed on the TO stock exchange, this Canada-based company holds position #17829 globally and #576 in its home market, demonstrating a -19.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncolytics Biotech Inc's stock price CA$14.90 by its total outstanding shares 100361000 (100.36 Million). Analyse Oncolytics Biotech Inc cash flow conversion to see how efficiently the company converts income to cash.
Oncolytics Biotech Inc Market Cap History: 2015 to 2025
Oncolytics Biotech Inc's market capitalization history from 2015 to 2025. Data shows growth from $265.53 Million to $1.08 Billion (10.98% CAGR).
Oncolytics Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncolytics Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ONC by Market Capitalization
Companies near Oncolytics Biotech Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Oncolytics Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Oncolytics Biotech Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Oncolytics Biotech Inc's market cap moved from $265.53 Million to $ 1.08 Billion, with a yearly change of 10.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CA$1.08 Billion | +1020.30% |
| 2024 | CA$96.56 Million | -25.70% |
| 2023 | CA$129.95 Million | -19.37% |
| 2022 | CA$161.17 Million | +26.86% |
| 2021 | CA$127.05 Million | -42.05% |
| 2020 | CA$219.25 Million | -50.89% |
| 2019 | CA$446.49 Million | +145.02% |
| 2018 | CA$182.23 Million | -62.79% |
| 2017 | CA$489.68 Million | +167.92% |
| 2016 | CA$182.77 Million | -31.17% |
| 2015 | CA$265.53 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Oncolytics Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $142.51 Million USD |
| MoneyControl | $142.51 Million USD |
| MarketWatch | $142.51 Million USD |
| marketcap.company | $142.51 Million USD |
| Reuters | $142.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more